NCT01771250View on ClinicalTrials.gov

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Insulin Peglispro

Daily doses administered SC.

BIOLOGICAL

Insulin Glargine

Daily doses administered SC.

Trial Locations (1)

8000

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01771250 - A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes | Biotech Hunter | Biotech Hunter